CrossBridge Bio
CrossBridge Bio is an innovative oncology company focused on developing advanced antibody-drug conjugates (ADCs) for cancer treatment. The company is dedicated to redefining cancer therapies through cutting-edge platform technologies, dual-payload ADCs, and strategic collaborations. With a strong leadership team and a focus on scientific excellence, CrossBridge Bio aims to bring transformative treatments to patients with unmet medical needs.
Industries
Nr. of Employees
small (1-50)
CrossBridge Bio
Texas Medical Center Innovation, 2450 Holcombe Blvd., Suite X, Houston, TX 77021
Products
Dual‑payload ADC development platform
Platform for designing and producing antibody‑drug conjugates that incorporate multiple payloads and optimized linker chemistry to improve stability and payload synergy.
TROP‑2‑targeting dual‑payload ADC candidate (lead preclinical program)
A lead oncology candidate designed to target TROP‑2 expressing solid tumors using a dual‑payload ADC format intended for IND‑enabling development.
Dual‑payload ADC development platform
Platform for designing and producing antibody‑drug conjugates that incorporate multiple payloads and optimized linker chemistry to improve stability and payload synergy.
TROP‑2‑targeting dual‑payload ADC candidate (lead preclinical program)
A lead oncology candidate designed to target TROP‑2 expressing solid tumors using a dual‑payload ADC format intended for IND‑enabling development.
Expertise Areas
- Antibody‑drug conjugate (ADC) development
- ADC linker chemistry and payload conjugation
- Bispecific antibody engineering and small‑molecule bispecific constructs
- Preclinical oncology models and in vivo efficacy testing
Key Technologies
- Dual‑payload / multi‑loaded ADC conjugation
- Protease‑cleavable peptide linkers (EGCit)
- Bispecific ADC constructs
- Antibody engineering and bispecific formats
News & Updates
The American Association for Cancer Research will take place from April 5 to April 10, 2024, at the San Diego Convention Center. CrossBridge Bios’ Daniel Pereira will attend the conference.
The ASCO Annual Meeting will be held from May 31 to June 4, 2024, at McCormick Place, Chicago.
CrossBridge Bio has received a grant from CPRIT to support its dual-payload ADC platform and TROP2 program, CBB-120, moving towards IND-enabling studies.
CrossBridge Bio has secured $10 million in seed funding to accelerate the development of its dual-payload ADCs, including CBB-120, for targeted cancer therapy.
CrossBridge Bio is developing next-generation ADCs with improved stability and multi-payload design, focusing on TROP-2-positive tumors.
The American Association for Cancer Research will take place from April 5 to April 10, 2024, at the San Diego Convention Center. CrossBridge Bios’ Daniel Pereira will attend the conference.
The ASCO Annual Meeting will be held from May 31 to June 4, 2024, at McCormick Place, Chicago.
CrossBridge Bio has received a grant from CPRIT to support its dual-payload ADC platform and TROP2 program, CBB-120, moving towards IND-enabling studies.
CrossBridge Bio has secured $10 million in seed funding to accelerate the development of its dual-payload ADCs, including CBB-120, for targeted cancer therapy.
CrossBridge Bio is developing next-generation ADCs with improved stability and multi-payload design, focusing on TROP-2-positive tumors.